Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509794 | 1.00 | FGFR1 (0.51) | FGFR1HPGDMEN1KMT2AMAPT | |
| SCHEMBL23675171 | 0.87 | HPGD (0.64) | FGFR1HPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL29244153 | 0.87 | HPGD (0.52) | FGFR1HPGDMEN1KMT2APOLB | |
| SCHEMBL31022748 | 0.87 | HPGD (0.52) | FGFR1HPGDMEN1KMT2APOLB | |
| SCHEMBL31022762 | 0.85 | HPGD (0.53) | FGFR1HPGDMEN1KMT2APOLB | |
| SCHEMBL29026031 | 0.85 | HPGD (0.53) | FGFR1HPGDMEN1KMT2APOLB | |
| SCHEMBL29244257 | 0.84 | HPGD (0.46) | FGFR1HPGDMEN1KMT2APOLB | |
| SCHEMBL6875300 | 0.82 | FGFR1 (0.76) | FGFR1HPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL29244198 | 0.82 | HPGD (0.47) | FGFR1HPGDMEN1KMT2APOLB | |
| SCHEMBL13202022 | 0.81 | HPGD (0.55) | FGFR1HPGDMAPTRAB9ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290419-A | Pyridoimidazole derivative, preparation method and application thereof | 成都硕德药业有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112714765-B | GABA A Receptor ligands | 萨尼奥纳有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3849976-B1 | A GABA A RECEPTOR LIGAND | SANIONA AS (DK) | 2022-10-26 | — | — | EP | disclosed |
| US-11396510-B2 | GABAA receptor ligand | SANIONA A/S (DK) | 2022-07-26 | — | — | US | disclosed |
| US-20210332042-A1 | A GABAA Receptor Ligand | SANIONA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| CN-112714765-A | GABAAReceptor ligands | 萨尼奥纳有限责任公司 | 2021-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332042-A1 | A GABAA Receptor Ligand | GABRA2, GABRA6, GABRA5 | FGFR1 2537/4885HPGD 2190/4885MEN1 4768/4885 |
| US-11396510-B2 | GABAA receptor ligand | GABRA2, GABRA3, GABRA6 | FGFR1 2518/4885HPGD 1982/4885MEN1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.